Home >> Research Area >>Natural Products>>Triterpenoids>> Chikusetsusaponin IVa

Chikusetsusaponin IVa

CAS# 51415-02-2

Chikusetsusaponin IVa

Catalog No. BCN3432----Order now to get a substantial discount!

Product Name & Size Price Stock
Chikusetsusaponin IVa: 5mg $23 In Stock
Chikusetsusaponin IVa: 10mg Please Inquire In Stock
Chikusetsusaponin IVa: 20mg Please Inquire Please Inquire
Chikusetsusaponin IVa: 50mg Please Inquire Please Inquire
Chikusetsusaponin IVa: 100mg Please Inquire Please Inquire
Chikusetsusaponin IVa: 200mg Please Inquire Please Inquire
Chikusetsusaponin IVa: 500mg Please Inquire Please Inquire
Chikusetsusaponin IVa: 1000mg Please Inquire Please Inquire

Quality Control of Chikusetsusaponin IVa

Number of papers citing our products

Chemical structure

Chikusetsusaponin IVa

3D structure

Chemical Properties of Chikusetsusaponin IVa

Cas No. 51415-02-2 SDF Download SDF
PubChem ID 3080813 Appearance White-off-white powder
Formula C42H66O14 M.Wt 795.0
Type of Compound Triterpenoids Storage Desiccate at -20°C
Synonyms Calenduloside F
Solubility DMSO : 100 mg/mL (125.79 mM; Need ultrasonic)
Chemical Name (2S,3S,4S,5R,6R)-6-[[(6aR,6bS,8aS,12aR,14bR)-4,4,6a,6b,11,11,14b-heptamethyl-8a-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycarbonyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
SMILES CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)OC6C(C(C(C(O6)C(=O)O)O)O)O)C)C)C2C1)C)C(=O)OC7C(C(C(C(O7)CO)O)O)O)C
Standard InChIKey YOSRLTNUOCHBEA-LSYFXOIVSA-N
Standard InChI InChI=1S/C42H66O14/c1-37(2)14-16-42(36(52)56-34-30(48)27(45)26(44)22(19-43)53-34)17-15-40(6)20(21(42)18-37)8-9-24-39(5)12-11-25(38(3,4)23(39)10-13-41(24,40)7)54-35-31(49)28(46)29(47)32(55-35)33(50)51/h8,21-32,34-35,43-49H,9-19H2,1-7H3,(H,50,51)/t21-,22-,23?,24?,25?,26-,27+,28+,29+,30-,31-,32+,34+,35-,39+,40-,41-,42+/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of Chikusetsusaponin IVa

1 Achyranthes sp. 2 Chenopodium sp. 3 Gardenia sp. 4 Hemsleya sp. 5 Ilex sp. 6 Panax sp. 7 Phytolacca sp.

Biological Activity of Chikusetsusaponin IVa

DescriptionChikusetsusaponin IVa is a novel AMPK activator, can induce insulin secretion from βTC3 cells via GPR40 mediated calcium and PKC pathways, may be developed into a new potential for therapeutic agent used in T2DM patients.Chikusetsusaponin IVa exerts antithrombotic effects, including minor hemorrhagic events.
TargetsAMPK | Wnt/β-catenin | CDK | PKC | GPR | GLUT | Calcium Channel
In vitro

Chikusetsusaponin IVa methyl ester induces cell cycle arrest by the inhibition of nuclear translocation of β-catenin in HCT116 cells.[Pubmed: 25749342]

Biochem Biophys Res Commun. 2015 Apr 17;459(4):591-6.

We demonstrate that Chikusetsusaponin IVa methyl ester (CME), a triterpenoid saponin from the root of Achyranthes japonica, has an anticancer activity.
METHODS AND RESULTS:
We investigate its molecular mechanism in depth in HCT116 cells. CME reduces the amount of β-catenin in nucleus and inhibits the binding of β-catenin to specific DNA sequences (TCF binding elements, TBE) in target gene promoters. Thus, CME appears to decrease the expression of cell cycle regulatory proteins such as Cyclin D1, as a representative target for β-catenin, as well as CDK2 and CDK4. As a result of the decrease of the cell cycle regulatory proteins, CME inhibits cell proliferation by arresting the cell cycle at the G0/G1 phase.
CONCLUSIONS:
Therefore, we suggest that CME as a novel Wnt/β-catenin inhibitor can be a putative agent for the treatment of colorectal cancers.

In vivo

Antithrombotic effect of chikusetsusaponin IVa isolated from Ilex paraguariensis (Maté).[Pubmed: 23134458]

J Med Food. 2012 Dec;15(12):1073-80.

The triterpene Chikusetsusaponin IVa was isolated from the fruit of Ilex paraguariensis.
METHODS AND RESULTS:
Using biochemical and pharmacological methods, we demonstrated that Chikusetsusaponin IVa (1) prolongs the recalcification time, prothrombin time, activated partial thromboplastin time, and thrombin time of normal human plasma in a dose-dependent manner, (2) inhibits the amidolytic activity of thrombin and factor Xa upon synthetic substrates S2238 and S2222, (3) inhibits thrombin-induced fibrinogen clotting (50% inhibition concentration, 199.4 ± 9.1 μM), and (4) inhibits thrombin- and collagen-induced platelet aggregation. The results also indicate that Chikusetsusaponin IVa preferentially inhibits thrombin in a competitive manner (K(i)=219.6 μM). Furthermore, when administered intravenously to rats, Chikusetsusaponin IVa inhibited thrombus formation in a stasis model of venous thrombosis, although it did not induce a significant bleeding effect. Chikusetsusaponin IVa also prolonged the ex vivo activated partial thromboplastin time.
CONCLUSIONS:
Altogether, these data suggest that Chikusetsusaponin IVa exerts antithrombotic effects, including minor hemorrhagic events. This appears to be important for the development of new therapeutic agents.

Protocol of Chikusetsusaponin IVa

Kinase Assay

Chikusetsu saponin IVa regulates glucose uptake and fatty acid oxidation: implications in antihyperglycemic and hypolipidemic effects.[Pubmed: 25677570]

J Pharm Pharmacol. 2015 Jul;67(7):997-1007.

The aim of this study is to investigate antidiabetic effects and molecular mechanisms of the chemical Chikusetsu saponin IVa (CHS) that isolated from root bark of Aralia taibaiensis, which has multiple pharmacological activity, such as relieving rheumatism, promoting blood circulation to arrest pain and antidiabetic action.
METHODS AND RESULTS:
Rats with streptozotocin/nicotinamide-induced type 2 diabetes mellitus (T2DM) and insulin-resistant myocytes were used. Adenosine monophosphate (AMP)-activated protein kinase (AMPK) and acetyl-CoA carboxylase were quantified by immunoblotting. Assays of glucose uptake, fatty acid oxidation, glucose transporter 4 (GLUT4) translocation and carnitine palmitoyl transferase-1 (CPT-1) activity were performed. Chronic oral administration of CHS effectively decreases blood glucose, triglyceride, free fatty acid (FFA) and low density lipoprotein-cholesterol levels in T2DM rats. In both normal and insulin-resistant C2C12 myocytes, CHS activates AMPK, and increases glucose uptake or fatty acid oxidation through enhancing membrane translocation of GLUT4 or CPT-1 activity respectively. Knockdown of AMPK significantly diminishes the effects of CHS on glucose uptake and fatty acid oxidation.
CONCLUSIONS:
CHS is a novel AMPK activator that is capable of bypassing defective insulin signalling and could be useful for the treatment of T2DM or other metabolic disorders.

Animal Research

Insulinotropic effect of Chikusetsu saponin IVa in diabetic rats and pancreatic β-cells.[Pubmed: 25701750]

J Ethnopharmacol. 2015 Apr 22;164:334-9.

As a well-known traditional Chinese medicine the root bark of Aralia taibaiensis has traditionally been used as the medicine considered alleviating several disorders including diabetes mellitus (DM). Chikusetsusaponin IVa (CHS) has been defined as a major active ingredient of triterpenoid saponins extracted from Aralia taibaiensis. The scientific evidence of anti-diabetic effect for Chikusetsusaponin IVa remains unknown and the purpose of our study was to study its hypoglycemic and insulin secretagogue activities.
METHODS AND RESULTS:
In vivo studies were performed on type 2 diabetic mellitus (T2DM) rats given Chikusetsusaponin IVa for 28 days to test the antihyperglycemic activity. The in vitro effects and possible mechanisms of Chikusetsusaponin IVa on the insulin secretion in pancreatic β-cell line βTC3 were determined. RESULTS: Oral administration of Chikusetsusaponin IVa dose-dependently increased the level of serum insulin and decreased the rise in blood glucose level in an in vivo treatment. In vitro, Chikusetsusaponin IVa potently stimulated the release of insulin from βTC3 cells at both basal and stimulatory glucose concentrations, the effect which was changed by the removal of extracellular Ca(2+). Two methods showed that Chikusetsusaponin IVa enhanced the intracellular calcium levels in βTC3 cells. Chikusetsusaponin IVa was capable of enhancing the phosphorylation of extracellular signal-regulated protein kinases C (PKC), which could be reversed by a PKC inhibitor (RO320432), and the insulin secretion induced by Chikusetsusaponin IVa was also inhibited by RO320432. Further study also showed that the insulinotropic effect, intracellular calcium levels and the phosphorylation of PKC were reduced by inhibiting G protein-coupled receptor 40 (GPR40) by a GPR40 inhibitor (DC126026).
CONCLUSIONS:
These observations suggest that the signaling of Chikusetsusaponin IVa -induced insulin secretion from βTC3 cells via GPR40 mediated calcium and PKC pathways and thus Chikusetsusaponin IVa might be developed into a new potential for therapeutic agent used in T2DM patients.

Chikusetsusaponin IVa Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Chikusetsusaponin IVa Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Chikusetsusaponin IVa

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.2579 mL 6.2893 mL 12.5786 mL 25.1572 mL 31.4465 mL
5 mM 0.2516 mL 1.2579 mL 2.5157 mL 5.0314 mL 6.2893 mL
10 mM 0.1258 mL 0.6289 mL 1.2579 mL 2.5157 mL 3.1447 mL
50 mM 0.0252 mL 0.1258 mL 0.2516 mL 0.5031 mL 0.6289 mL
100 mM 0.0126 mL 0.0629 mL 0.1258 mL 0.2516 mL 0.3145 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Chikusetsusaponin IVa

Chikusetsusaponin IVa a major active ingredient of triterpenoid saponins, exerts antithrombotic effects, including minor hemorrhagic events. This appears to be important for the development of new therapeutic agents. a novel AMPK activator that is capable of bypassing defective insulin signalling and could be useful for the treatment of T2DM or other metabolic disorders. IC50 Value: 199.4 ± 9.1 μM (inhibiting thrombin-induced fibrinogen clotting) Target: In vitro: Using biochemical and pharmacological methods, it proves that chikusetsusaponin IVa prolongs the recalcification time, prothrombin time, activated partial thromboplastin time, and thrombin time of normal human plasma in a dose-dependent manner; inhibits the amidolytic activity of thrombin and factor Xa upon synthetic substrates S2238 and S2222; inhibits thrombin-induced fibrinogen clotting (50% inhibition concentration, 199.4 ± 9.1 μM); inhibits thrombin- and collagen-induced platelet aggregation. Chikusetsusaponin IVa can also preferentially inhibits thrombin in a competitive manner (K(i)=219.6 μM) [1]. Chikusetsusaponin IVa suppresses the production of iNOS, COX-2, IL-1β, IL-6, and TNF-α in LPS-stimulated THP-1 cells likely by inhibiting NF-κB activation and ERK, JNK, and p38 signal pathway phosphorylation [2]. In vivo: Studies were performed on type 2 diabetic mellitus (T2DM) rats given CHS for 28 days to test the antihyperglycemic activity. Oral administration of CHS dose-dependently increased the level of serum insulin and decreased the rise in blood glucose level [3].

References:
[1]. Wang H, et al.Inhibitory effects of Chikusetsusaponin IVa on lipopolysaccharide-induced pro-inflammatory responses in THP-1 cells. Int J Immunopathol Pharmacol. 2015 Jul 8. [2]. Cui J, et al. Insulinotropic effect of Chikusetsu saponin IVa in diabetic rats and pancreatic β-cells. J Ethnopharmacol. 2015 Apr 22;164:334-9. [3]. Li Y, et al. Chikusetsu saponin IVa regulates glucose uptake and fatty acid oxidation: implications in antihyperglycemic and hypolipidemic effects. J Pharm Pharmacol. 2015 Jul;67(7):997-1007. [4]. Dahmer T, et al. Antithrombotic effect of chikusetsusaponin IVa isolated from Ilex paraguariensis (Maté). J Med Food. 2012 Dec;15(12):1073-80.

Featured Products
New Products
 

References on Chikusetsusaponin IVa

Insulinotropic effect of Chikusetsu saponin IVa in diabetic rats and pancreatic beta-cells.[Pubmed:25701750]

J Ethnopharmacol. 2015 Apr 22;164:334-9.

ETHNOPHARMACOLOGICAL RELEVANCE: As a well-known traditional Chinese medicine the root bark of Aralia taibaiensis has traditionally been used as the medicine considered alleviating several disorders including diabetes mellitus (DM). Chikusetsu saponin IVa (CHS) has been defined as a major active ingredient of triterpenoid saponins extracted from Aralia taibaiensis. The scientific evidence of anti-diabetic effect for CHS remains unknown and the purpose of our study was to study its hypoglycemic and insulin secretagogue activities. MATERIALS AND METHODS: In vivo studies were performed on type 2 diabetic mellitus (T2DM) rats given CHS for 28 days to test the antihyperglycemic activity. The in vitro effects and possible mechanisms of CHS on the insulin secretion in pancreatic beta-cell line betaTC3 were determined. RESULTS: Oral administration of CHS dose-dependently increased the level of serum insulin and decreased the rise in blood glucose level in an in vivo treatment. In vitro, CHS potently stimulated the release of insulin from betaTC3 cells at both basal and stimulatory glucose concentrations, the effect which was changed by the removal of extracellular Ca(2+). Two methods showed that CHS enhanced the intracellular calcium levels in betaTC3 cells. CHS was capable of enhancing the phosphorylation of extracellular signal-regulated protein kinases C (PKC), which could be reversed by a PKC inhibitor (RO320432), and the insulin secretion induced by CHS was also inhibited by RO320432. Further study also showed that the insulinotropic effect, intracellular calcium levels and the phosphorylation of PKC were reduced by inhibiting G protein-coupled receptor 40 (GPR40) by a GPR40 inhibitor (DC126026). CONCLUSION: These observations suggest that the signaling of CHS-induced insulin secretion from betaTC3 cells via GPR40 mediated calcium and PKC pathways and thus CHS might be developed into a new potential for therapeutic agent used in T2DM patients.

Antithrombotic effect of chikusetsusaponin IVa isolated from Ilex paraguariensis (Mate).[Pubmed:23134458]

J Med Food. 2012 Dec;15(12):1073-80.

The triterpene Chikusetsusaponin IVa was isolated from the fruit of Ilex paraguariensis. Using biochemical and pharmacological methods, we demonstrated that Chikusetsusaponin IVa (1) prolongs the recalcification time, prothrombin time, activated partial thromboplastin time, and thrombin time of normal human plasma in a dose-dependent manner, (2) inhibits the amidolytic activity of thrombin and factor Xa upon synthetic substrates S2238 and S2222, (3) inhibits thrombin-induced fibrinogen clotting (50% inhibition concentration, 199.4 +/- 9.1 muM), and (4) inhibits thrombin- and collagen-induced platelet aggregation. The results also indicate that Chikusetsusaponin IVa preferentially inhibits thrombin in a competitive manner (K(i)=219.6 muM). Furthermore, when administered intravenously to rats, Chikusetsusaponin IVa inhibited thrombus formation in a stasis model of venous thrombosis, although it did not induce a significant bleeding effect. Chikusetsusaponin IVa also prolonged the ex vivo activated partial thromboplastin time. Altogether, these data suggest that Chikusetsusaponin IVa exerts antithrombotic effects, including minor hemorrhagic events. This appears to be important for the development of new therapeutic agents.

Chikusetsu saponin IVa regulates glucose uptake and fatty acid oxidation: implications in antihyperglycemic and hypolipidemic effects.[Pubmed:25677570]

J Pharm Pharmacol. 2015 Jul;67(7):997-1007.

OBJECTIVES: The aim of this study is to investigate antidiabetic effects and molecular mechanisms of the chemical Chikusetsu saponin IVa (CHS) that isolated from root bark of Aralia taibaiensis, which has multiple pharmacological activity, such as relieving rheumatism, promoting blood circulation to arrest pain and antidiabetic action. METHODS: Rats with streptozotocin/nicotinamide-induced type 2 diabetes mellitus (T2DM) and insulin-resistant myocytes were used. Adenosine monophosphate (AMP)-activated protein kinase (AMPK) and acetyl-CoA carboxylase were quantified by immunoblotting. Assays of glucose uptake, fatty acid oxidation, glucose transporter 4 (GLUT4) translocation and carnitine palmitoyl transferase-1 (CPT-1) activity were performed. KEY FINDINGS: Chronic oral administration of CHS effectively decreases blood glucose, triglyceride, free fatty acid (FFA) and low density lipoprotein-cholesterol levels in T2DM rats. In both normal and insulin-resistant C2C12 myocytes, CHS activates AMPK, and increases glucose uptake or fatty acid oxidation through enhancing membrane translocation of GLUT4 or CPT-1 activity respectively. Knockdown of AMPK significantly diminishes the effects of CHS on glucose uptake and fatty acid oxidation. CONCLUSIONS: CHS is a novel AMPK activator that is capable of bypassing defective insulin signalling and could be useful for the treatment of T2DM or other metabolic disorders.

Chikusetsusaponin IVa methyl ester induces cell cycle arrest by the inhibition of nuclear translocation of beta-catenin in HCT116 cells.[Pubmed:25749342]

Biochem Biophys Res Commun. 2015 Apr 17;459(4):591-6.

We demonstrate that Chikusetsusaponin IVa methyl ester (CME), a triterpenoid saponin from the root of Achyranthes japonica, has an anticancer activity. We investigate its molecular mechanism in depth in HCT116 cells. CME reduces the amount of beta-catenin in nucleus and inhibits the binding of beta-catenin to specific DNA sequences (TCF binding elements, TBE) in target gene promoters. Thus, CME appears to decrease the expression of cell cycle regulatory proteins such as Cyclin D1, as a representative target for beta-catenin, as well as CDK2 and CDK4. As a result of the decrease of the cell cycle regulatory proteins, CME inhibits cell proliferation by arresting the cell cycle at the G0/G1 phase. Therefore, we suggest that CME as a novel Wnt/beta-catenin inhibitor can be a putative agent for the treatment of colorectal cancers.

Description

Chikusetsusaponin IVa a major active ingredient of triterpenoid saponins, exerts antithrombotic effects, including minor hemorrhagic events.

Keywords:

Chikusetsusaponin IVa,51415-02-2,Calenduloside F,Natural Products, buy Chikusetsusaponin IVa , Chikusetsusaponin IVa supplier , purchase Chikusetsusaponin IVa , Chikusetsusaponin IVa cost , Chikusetsusaponin IVa manufacturer , order Chikusetsusaponin IVa , high purity Chikusetsusaponin IVa

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: